SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 124 filers reported holding SAGE THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is 2.96 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $72,517,000 | +32.4% | 1,420,226 | +19.4% | 0.01% | +18.2% |
Q3 2016 | $54,758,000 | +75.1% | 1,189,093 | +14.6% | 0.01% | +57.1% |
Q2 2016 | $31,273,000 | +23.9% | 1,037,928 | +31.8% | 0.01% | +16.7% |
Q1 2016 | $25,249,000 | -35.6% | 787,546 | +17.1% | 0.01% | -33.3% |
Q4 2015 | $39,208,000 | +25.5% | 672,519 | -8.9% | 0.01% | +12.5% |
Q3 2015 | $31,251,000 | -38.4% | 738,434 | +6.3% | 0.01% | -33.3% |
Q2 2015 | $50,696,000 | +109.6% | 694,471 | +44.2% | 0.01% | +100.0% |
Q1 2015 | $24,188,000 | +43.1% | 481,540 | +4.2% | 0.01% | +50.0% |
Q4 2014 | $16,907,000 | +279.0% | 461,948 | +226.2% | 0.00% | +300.0% |
Q3 2014 | $4,461,000 | – | 141,607 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
RA Capital Management | 350,933 | $49,569,000 | 2.65% |
Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |